A new study conducted by IBM and Silico Research showed that biopharmaceutical companies that do not partner or collaborate with other companies, risk delays in the production of new medicines, medical devices, diagnostics and support services. “The Industry is at risk of delaying new targeted treatment solutions if biopharmaceutical companies do not collaborate more effectively,” said Guy Lefever, who leads IBM’s Global Life Sciences practice. The survey, An Imperfect Harmo...